Sakura, T
,
Hayakawa, F
Sugiura, I
Murayama, T
Imai, K
Usui, N
Fujisawa, S
Yamauchi, T
Yujiri, T http://orcid.org/0000-0001-6838-3456
Kakihana, K
Ito, Y
Kanamori, H
Ueda, Y
Miyata, Y
Kurokawa, M
Asou, N
Ohnishi, K
Ohtake, S http://orcid.org/0000-0003-0112-6564
Kobayashi, Y http://orcid.org/0000-0003-2378-7865
Matsuo, K http://orcid.org/0000-0003-1761-6314
Kiyoi, H
Miyazaki, Y
Naoe, T
Article History
Received: 29 April 2017
Revised: 21 August 2017
Accepted: 23 August 2017
First Online: 15 September 2017
Competing interests
: Employment: TS (Astellas Pharma) and MK (Celgene, Shionogi, Daiichi Sankyo Foundation of Life Science). Consultancy: TS (Astellas Pharma), NU (CIMIC, Takeda Bio Development Center, Lilly Japan, Pfizer, Nippon Boehiringer-Ingleheim, Sysmex, Janssen, Zenyaku Kogyo, Kyowa hakko Kirin, Astellas Pharma, Otsuka Pharmaceutical, Celgene, SymBio Phrmaceuticals, Huya Bioscience International), YK (Boehiringer-Ingleheim, Novartis), H Kiyoi (Daiichi Sankyo, Celgene, Astellas Pharma, Quintiles), Y Miyazaki (Otsuka, Shire) and TN (Astellas Pharma, Otsuka Pharmaceutical Factory, Fujifilm, Nippon Boehiringer-Ingleheim, Celgene, Dainippon Sumitomo Pharma, Kyowa Hakko Kirin, Pfizer, Toyama Chemical). Stock Ownership: none. Honoraria: FH (Nippon Shinyaku, Dainippon Sumitomo Pharma, Asahi Kasei, Kyowa hakko Kirin, Meiji Seika Pharma), TM (Kyowa Hakko Kirin, Nippon Shinyaku, Taiho Pharmaceutical, Janssen, Siemens, Novartis, Celgene, Ono Pharmaceutical, Pfizer, Bristol-Myers Squibb, Eisai), NU (Chugai Pharmaceutical, Bristol-Myers Squibb, Pfizer, Kyowa Hakko Kirin), SF (Bristol-Myers Squibb, Chugai Pharmaceutical, Celgene, Takeda Pharmaceuticals, Ono Phamaceutical, Pfizer, Alexion Phamaceutical, Shire plc, SHIONOGI CO., LTD, Otsuka Phamaceutical, Sumitomo Dainippon Pharma, Nippon Shinyaku, Astellas Pharma, Novartis, Janssen Pharmaceutical, Eisai, Beckman Coulter), KK (Chugai Pharma, Bristol-Myers Squibb, Kyowa Hakko Kirin, Dainippon Sumitomo Pharma, Celgene), YI (Kyowa Hakko Kirin), H Kanamori (Novartis, Chugai Pharma, Kyowa Hakko Kirin), MK (Kagakuhyoronsha, Nankodo, MSD, Kyowa Hakko Kirin, Ketsuekijohohiroba Tsubasa, Nippon Shinyaku, Yakult, Pfizer, Hokuryukan, Shire, Daiichi Sankyo, New Science, Ono Pharmaceutical, Dainippon Sumitomo Pharma, Celgene, Bristol-Myers Squibb, Takeda), H Kiyoi (Kyowa Hakko Kirin, Pfizer, Shire, Ono Pharmaceutical, Dainippon Sumitomo Pharma, Celgene, Bristol-Myers Squibb, Takeda, Astellas Pharma, Mochida Pharmaceutical, Chugai Pharma, Fujifilm, Alexion Pharmaceuticals, Nippon Kayaku, Sysmex, Amgen Astellas Biopharma, Novartis, Otsuka), Y Miyazaki (Kyowa Hakko Kirin, Celgene, Nippon Shinyaku, Chugai Pharma, Astellas Pharma) and TN (Nippon Boehiringer-Ingleheim, Chugai Pharma, Dainippon Sumitomo Pharma, Kyowa Hakko Kirin, Sysmex, Amgen Astellas Biopharma, Alexion Pharmaceuticals, Daiichi Sankyo, Agios, Eisai). Research Funding: TS (Otsuka Pharmaceutical Factory), NU (Bristol-Myers Squibb, Novartis, Nippon Shinyaku, Fujimoto Pharmaceutical, Celgene, Pfizer), SF (Otsuka Pharmaceutical, Kyowa Hakko Kirin, Ono Pharmaceutical, Chugai Pharmaceutical, Takeda Pharmaceutical, Pfizer, SHIONOGI CO., LTD, Nippon Shinyaku, Astellas Pharma, MSD), MK (Teijin Pharma, Pfizer, MSD, Toyama Chemical, Astellas Pharma, Kyowa Hakko Kirin, Chugai Pharma), NA (Toyama Chemical, Chugai Pharma), YK (Otsuka Pharmaceutical, Pfizer, Takeda, Astellas Pharma, Daiichi Sankyo) and H Kiyoi (Kyowa Hakko Kirin, Pfizer, Dainippon Sumitomo Pharma, Takeda, Astellas Pharma, Mochida Pharmaceutical, Chugai Pharma, Fujifilm, Alexion Pharmaceuticals, Novartis, Nippon Boehiringer-Ingleheim, Toyama Chemical, Zenyaku Kogyo, Nippon Shinyaku, Yakult, Eisai, MSD, JCR Pharma, Meiji Seika Pharma).Expert Testimony: none. Other potential financial relationships: none.